||ORD 6 3/7P
||EPS - Basic
||Market Cap (m)
|Software & Computer Services
Microgen Share Discussion Threads
Showing 1201 to 1225 of 1225 messages
|Trading update due soon I believe.|
|what a performance, YTD +82.4%|
|I wonder.Had an itchy finger then i noticed the volume today and last week.I think that was down to the Wellcome Trust reducing but i could be wrong.
Not complaining.Is this an all time high if you take in the share consolidation?|
|Why all the volume ?? Is something going on I wonder|
|Different strategy & snr management now to that over the last 5 yrs, chalk & cheese. City starting to notice the company being re-invigorated in my opinion (first buys in Nov 15 for me, +37% to date, not too boring :)
Decent volume yesterday and enough in the results to generate more interest.
Kestrel still building stake ?|
|So what about the share consolidation and special dividends in that time?|
|held these years ago
hasn't done much for 5 years
|Interim results to June 30th;
-- The Group continues to make good progress towards its strategic objectives
-- Revenue growth of 23% to GBP19.5 million (H1, 2015: GBP15.8 million)
-- Group adjusted operating profit increased by 16% to GBP4.6 million (H1, 2015: GBP3.9 million)*. Group operating profit on a statutory basis of GBP4.0 million (H1, 2015: GBP3.9 million)
-- Adjusted basic earnings per share increased to 5.9 pence (H1, 2015: 4.3 pence). Basic earnings per share increased to 5.1 pence (H1, 2015: 4.2 pence)
-- Interim dividend increased to 1.5 pence per share (2015: 1.4 pence per share)
-- Strong balance sheet with cash of GBP12.7 million (H1, 2015: GBP15.6 million) and net funds of GBP1.0 million (H1, 2015: GBP0.9 million) following net corporate cash outflows of GBP4.4 million in the past 12 months (dividends, net acquisition consideration and property disposal)|
|Tech Market View - 16/5/16:
Microgen buys again in Trust Admin sector
Our recent meeting with Microgen’s top management confirmed our view that the company is picking up the pace, as well as adopting a more open approach to the City and analysts. The Group has some good news to deliver with a confident view of its strategy and growth prospects.
The Financial Systems business (48% of Group revenue, at £15.2m) is continuing to build in the Trust and Fund Administration (T&FA) market with another small acquisition, this time of Cyprus-based Infoscreen. This will give access to Infoscreen’s 200-strong customer list, presenting new sales opportunities for Microgen’s 5Series product suite. The T&FA market is a complex market niche where increasing regulatory and governmental oversight is driving growth, but where the larger software providers are generally not active. Microgen has been able to build a leadership position and its policy of growing its customer list through small acquisitions (see here) is paying off, as T&FA revenues grew 38% last year. Overall the Financial Systems business grew by 6% as the legacy application management business declined. Looking ahead, Microgen is still looking for similar deals in T&FA and will be driving add-on sales through enhanced services (dashboards, workflow management, etc.) and opening up adjacent markets.
The other Group business, Aptitude Software, also looks set for further growth as financial services companies increasingly use its Application Platform to accelerate solution development and adopt the Group’s specialised finance applications. Microgen is also extending into the telecommunications sector through its new Revenue Recognition Engine to enable compliance with new reporting requirements. Additional work with partners should also accelerate growth.
Microgen looks set for faster progress, particularly now that the constraining policy of returning large amounts of cash to shareholders (in addition to dividends) is a thing of the past.|
|What a share this has been this year. I've done very well out of these in the past but just didn't fancy it at £1 so missed out this time. Well done to those who kept the faith :)|
|Another nice bolt on acquisition.
Buying Infoscreen of Cyprus) for E1.8M,recurring revenues.Looks to be a good strategic fit.|
|Read Stockdale Securities's note on MICROGEN, out this morning, by visiting hxxps://www.research-tree.com/company/GB00BVVHWX30
"Since October 2008, Microgen has returned c.£70m to shareholders via dividends, special dividends, tender offers, etc. This is equivalent to 190% of the market capitalisation at the time of the initiation of the programme. Despite returning c.£20m via a tender offer in early 2015, Microgen maintained the cash pay-out on the reduced number of shares for 2015, leading to a 27% increase in the dividend to 4.2%. With the group continuing to have strong organic growth prospects in the Aptitude Software business and the opportunity for further bolt-on acquisitions in the Financial Systems business, we believe that Microgen can continue to deliver a premium return to its shareholders...."|
|Chart looks fantastic.. Break out|
|It just doesn't want to go down.|
|They drop the offer then some big buys.|
|Thanks Shauney, hadn't seen the Investec revision.|
|Not sure target wise.Happy to hold anyway after the last results.They have net cash,EPS up 25%,dividend up 20%.
On March 3 Investec upped their target to 160p|
|Thanks Simon, noticed you were one of the few who picked MCGN in the annual stockchallenge as well, not doing too badly so far !
One of the reasons I held off a top up was the fact it was looking very overbought but given the illiquid nature of the stock perhaps I shouldn't have been so worried as the share price has powered on.|
Chart wise next targets are 154p then 176p.|
|Just gutted I didn't top up with some more a few weeks back, waiting for the pullback that never came. Any thoughts on share price target ? Its just about hit current broker targets.|
|Held on through grited teeth after the share special consolidation.Patience is being rewarded here.|
|So that's the end of Martyn Ratcliffe, RNS confirmed sale of remaining 4.1m shares to (assumption) unnamed institutional buyer. No impact on share price to date, looking overbought but note Investec have 143p target with FY16 EPS forecast of 8.7p (vs 9.2p adjusted EPS FY15). 3 year average PE 17.8 vs 14.5 based on that 9.2p. Still looking good on that basis....
Going ex dividend 28th April for 2.8p.|
|Through resistance at 133, a 2 yr high. Next level is 142, by my reckoning.|
|8.2m shares traded Friday ?!
If thats right we're due an RNS I think|